These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 12453537)

  • 1. The importance of anemia and its correction in the management of severe congestive heart failure.
    Silverberg DS; Wexler D; Iaina A
    Eur J Heart Fail; 2002 Dec; 4(6):681-6. PubMed ID: 12453537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoietin in heart failure.
    Silverberg DS; Wexler D; Blum M; Iaina A; Sheps D; Keren G; Schwartz D
    Semin Nephrol; 2005 Nov; 25(6):397-403. PubMed ID: 16298262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations.
    Silverberg DS; Wexler D; Blum M; Keren G; Sheps D; Leibovitch E; Brosh D; Laniado S; Schwartz D; Yachnin T; Shapira I; Gavish D; Baruch R; Koifman B; Kaplan C; Steinbruch S; Iaina A
    J Am Coll Cardiol; 2000 Jun; 35(7):1737-44. PubMed ID: 10841219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron?
    Silverberg DS; Wexler D; Iaina A
    J Nephrol; 2004; 17(6):749-61. PubMed ID: 15593047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anemia, chronic renal disease and congestive heart failure--the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists.
    Silverberg DS; Wexler D; Iaina A; Steinbruch S; Wollman Y; Schwartz D
    Int Urol Nephrol; 2006; 38(2):295-310. PubMed ID: 16868702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.
    Palazzuoli A; Silverberg D; Iovine F; Capobianco S; Giannotti G; Calabrò A; Campagna SM; Nuti R
    Am Heart J; 2006 Dec; 152(6):1096.e9-15. PubMed ID: 17161060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The interaction between heart failure and other heart diseases, renal failure, and anemia.
    Silverberg DS; Wexler D; Iaina A; Schwartz D
    Semin Nephrol; 2006 Jul; 26(4):296-306. PubMed ID: 16949468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiorenal anemia syndrome: do erythropoietin and iron therapy have a place in the treatment of heart failure?
    Pagourelias ED; Koumaras C; Kakafika AI; Tziomalos K; Zorou PG; Athyros VG; Karagiannis A
    Angiology; 2009; 60(1):74-81. PubMed ID: 18413330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin in heart failure and other cardiovascular diseases: hematopoietic and pleiotropic effects.
    Manolis AS; Tzeis S; Triantafyllou K; Michaelidis J; Pyrros I; Sakellaris N; Kranidis A; Melita H
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Oct; 5(5):355-75. PubMed ID: 16248829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
    Dimković N
    Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoietin should be part of congestive heart failure management.
    Silverberg DS; Wexler D; Blum M; Schwartz D; Wollman Y; Iaina A
    Kidney Int Suppl; 2003 Nov; (87):S40-7. PubMed ID: 14531772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of anemia in patients with congestive heart failure.
    Tim Goodnough L; Comin-Colet J; Leal-Noval S; Ozawa S; Takere J; Henry D; Javidroozi M; Hohmuth B; Bisbe E; Gross I; Shander A
    Am J Hematol; 2017 Jan; 92(1):88-93. PubMed ID: 27779769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study.
    Silverberg DS; Wexler D; Sheps D; Blum M; Keren G; Baruch R; Schwartz D; Yachnin T; Steinbruch S; Shapira I; Laniado S; Iaina A
    J Am Coll Cardiol; 2001 Jun; 37(7):1775-80. PubMed ID: 11401110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence, prognostic importance and therapeutic implications of anemia in heart failure.
    Mishra TK; Mishra SK; Mohanty NK; Rath PK
    Indian Heart J; 2005; 57(6):670-4. PubMed ID: 16521636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy insight: congestive heart failure, chronic kidney disease and anemia, the cardio-renal-anemia syndrome.
    Iaina A; Silverberg DS; Wexler D
    Nat Clin Pract Cardiovasc Med; 2005 Feb; 2(2):95-100. PubMed ID: 16265380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anaemia management in cardio renal disease.
    Silverberg DS; Wexler D; Iaina A; Schwartz D
    J Ren Care; 2010 May; 36 Suppl 1():86-96. PubMed ID: 20586904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The correction of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and the renal failure and markedly reduces hospitalization.
    Silverberg DS; Wexler D; Blum M; Tchebiner J; Sheps D; Keren G; Schwartz D; Baruch R; Yachnin T; Shaked M; Zubkov A; Steinbruch S; Iaina A
    Clin Nephrol; 2002 Jul; 58 Suppl 1():S37-45. PubMed ID: 12227725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anemia in heart failure: implications, management, and outcomes.
    Paul S; Paul RV
    J Cardiovasc Nurs; 2004; 19(6 Suppl):S57-66. PubMed ID: 15529075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indexes of the erythropoietin level in the blood plasma of chronic heart failure patients with anemia.
    Zahidova KK
    J Basic Clin Physiol Pharmacol; 2018 Jan; 29(1):11-17. PubMed ID: 29220885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of erythropoiesis stimulating agents and intravenous (IV) iron in the cardio renal anemia syndrome.
    Silverberg DS
    Heart Fail Rev; 2011 Nov; 16(6):609-14. PubMed ID: 20865450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.